Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Namibia - English - Namibia Medicines Regulatory Council

sandoz sa (pty) ltd - octreotide acetate - injection - each 1 ml solution for injection contains; octreotide acetate equivalent to octreotide 0.05 mg

Namibia - English - Namibia Medicines Regulatory Council

sandoz sa (pty) ltd - octreotide acetate - injection - each 1 ml solution for injection contains; octreotide acetate equivalent to octreotide 0.1 mg

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - bynfezia pen is indicated to reduce blood levels of growth hormone (gh) and insulin-like growth factor 1 (igf-1) [somatomedin c] in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. bynfezia pen is indicated for the treatment of adult patients with severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. bynfezia pen is indicated for the treatment of adult patients with the profuse watery diarrhea associated with vip-secreting tumors. in patients with acromegaly, the effect of bynfezia pen on improvement in clinical signs and symptoms, reduction in tumor size, and rate of growth has not been determined. in patients with carcinoid syndrome and vipomas, the effect of bynfezia pen on the tumor size, rate of growth and development of metastases has not been determined. bynfezia pen is contraindicated in patients with: - hypersensitivity to octreot

Malta - English - Medicines Authority

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 50 µg/ml - pituitary and hypothalamic hormones and analogues

Malta - English - Medicines Authority

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 100 µg/ml - pituitary and hypothalamic hormones and analogues

Malta - English - Medicines Authority

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 500 µg/ml - pituitary and hypothalamic hormones and analogues

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base - solution for injection - 0.05 mg/ml - active: octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base - solution for injection - 0.1 mg/ml - active: octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection